Phase II Pilot Trial of an Indoleamine 2, 3,diosygenase -1 (IDO1) Inhibitor (INCBO24360) Plus a Multipeptide Melanoma Vaccine (MELTAC 12.1) in Patients with Advanced Melanoma (CITN-04)

Administered By

Awarded By

Contributors

Start/End

  • September 21, 2017 - August 31, 2018